Aptinyx (Aptinyx) Total Liabilities : $29.71 Mil (As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptinyx Total Liabilities?

Aptinyx's Total Liabilities for the quarter that ended in Mar. 2023 was $29.71 Mil.

Aptinyx's quarterly Total Liabilities increased from Sep. 2022 ($27.41 Mil) to Dec. 2022 ($28.40 Mil) and increased from Dec. 2022 ($28.40 Mil) to Mar. 2023 ($29.71 Mil).

Aptinyx's annual Total Liabilities increased from Dec. 2020 ($4.70 Mil) to Dec. 2021 ($20.17 Mil) and increased from Dec. 2021 ($20.17 Mil) to Dec. 2022 ($28.40 Mil).

Aptinyx Total Liabilities Historical Data

The historical data trend for Aptinyx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptinyx Total Liabilities Chart

Aptinyx Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

6.30

5.17

4.70

20.17

28.40

Aptinyx Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Liabilities	Get a 7-Day Free Trial															29.17	30.21	27.41	28.40	29.71

Aptinyx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aptinyx's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.291	+	(22.108	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	28.40

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	66.684	-	38.285
	=	28.40

Aptinyx's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.323	+	(20.384	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	29.71

Total Liabilities	=	Total Assets (Q: Mar. 2023 )	-	Total Equity (Q: Mar. 2023 )
	=	47.963	-	18.256
	=	29.71

Aptinyx Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aptinyx's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptinyx (Aptinyx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptinyx Inc (OTCPK:APTX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

909 Davis Street, Suite 600, Evanston, IL, USA, 60201

Website

https://www.aptinyx.com

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Executives

Joan W. Miller	director	C/O APTINYX INC., 909 DAVIS ST., SUITE 600, EVANSTON IL 60201
Norbert G Riedel	director, officer: CEO and President	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Ashish Khanna	officer: CFO and CBO	909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Robert J. Hombach	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Gilmore Neil O'neill	director	215 FIRST STREET, CAMBRIDGE MA 02142
Bain Capital Life Sciences Investors, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Rachel E. Sherman	director	909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Bain Capital Life Sciences Fund, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Partners, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Jeffrey Lawrence Schwartz	10 percent owner	C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Bcip Life Sciences Associates, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Henry O Gosebruch	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Patrick G Enright	director, 10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025